Phaseline

Targets › SMO

SMO (Protein smoothened): drug programs, companies and trials

8 programs from 8 companies in 11 trials: 8 Phase 2, 3 Phase 1; Oncology, Respiratory; next expected readout Dec 2026.

G protein-coupled receptor, which transduces the smoothened signaling pathway. Activated by cholesterol in response to hedgehog (DHH, IHH or SHH) morphogens. (UniProt, Q99835)

Open in Phaseline: the race on SMO, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Gruppo Oncologico del Nord-OvestSonidegib
Smoothened homolog inhibitor
SMOPhase 2Locally Advanced Basal Cell CarcinomaDec 2026
National Cancer Institute (NCI)Vismodegib (GDC-0449)
Smoothened homolog inhibitor
SMOPhase 2Advanced Lymphoma; Clear Cell Chondrosarcoma; Adult Solid NeoplasmDec 2026
University of FloridaSonidegib
Smoothened homolog inhibitor
SMOPhase 2Hepatocellular CarcinomaApr 2027
University of California, IrvineGlasdegib
Smoothened homolog antagonist
SMOPhase 2Acute Myelogenous Leukemia (AML) Due to TherapyJun 2027
VA Office of Research and DevelopmentItraconazole
Cytochrome P450 51 inhibitor
SMO, AKT1, VEGFAPhase 2Esophageal AdenocarcinomaApr 2029
University Hospital, LilleSonidegib
Smoothened homolog inhibitor
SMOPhase 2Basal Cell CarcinomaJun 2029
Endeavor BiomedicinesTaladegib (ENV-101)
Smoothened homolog antagonist
SMOPhase 2Idiopathic Pulmonary Fibrosis–
Nathalie ZeitouniSonidegib
Smoothened homolog inhibitor
SMOPhase 1Basal Cell Carcinoma (BCC)Dec 2026

Conditions

Idiopathic Pulmonary Fibrosis (2) Locally Advanced Basal Cell Carcinoma (1) Basal Cell Carcinoma (BCC) (1) Acute Myelogenous Leukemia (AML) Due to Therapy (1) Advanced Lymphoma (1) Clear Cell Chondrosarcoma (1) Adult Solid Neoplasm (1) Basal Cell Carcinoma (1) Hepatocellular Carcinoma (1) Esophageal Adenocarcinoma (1)

Modalities

small molecule (8)

Companies

Gruppo Oncologico del Nord-Ovest (1) Nathalie Zeitouni (1) University of California, Irvine (1) Endeavor Biomedicines (1) National Cancer Institute (NCI) (1) University Hospital, Lille (1) University of Florida (1) VA Office of Research and Development (1)

Related targets

AKT1 (1) VEGFA (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.